Thermogenesis Holdings Inc (THMO)

$0.29

Market is closed - opens 7 PM, 11 Sep 2024

Performance

  • $0.29
    $0.29
    $0.29
    downward going graph

    0.0%

    Downside

    Day's Volatility :0.0%

    Upside

    0.0%

    downward going graph
  • $0.29
    $1.82
    $0.29
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :84.07%

    Upside

    84.07%

    downward going graph

Returns

PeriodThermogenesis Holdings IncIndex (Russel 2000)
3 Months
-55.36%
0.0%
6 Months
-68.75%
0.0%
1 Year
-78.99%
0.0%
3 Years
-99.77%
-20.6%

Highlights

Market Capitalization
4.0M
Book Value
$0.12
Earnings Per Share (EPS)
-5.24
Wall Street Target Price
5.0
Profit Margin
-153.43%
Operating Margin TTM
-20.35%
Return On Assets TTM
-25.5%
Return On Equity TTM
-801.94%
Revenue TTM
9.6M
Revenue Per Share TTM
3.14
Quarterly Revenue Growth YOY
6.4%
Gross Profit TTM
3.5M
EBITDA
-4.9M
Diluted Eps TTM
-5.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.01
EPS Estimate Next Quarter
0.02

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Thermogenesis Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1624.14%

Current $0.29
Target $5.00

Company Financials

FY18Y/Y Change
Revenue
9.7M
↓ 33.41%
Net Income
-39.7M
↑ 36.5%
Net Profit Margin
-410.63%
↓ 210.32%
FY19Y/Y Change
Revenue
13.0M
↑ 34.89%
Net Income
-9.5M
↓ 76.09%
Net Profit Margin
-72.79%
↑ 337.84%
FY20Y/Y Change
Revenue
9.7M
↓ 25.32%
Net Income
-16.4M
↑ 72.17%
Net Profit Margin
-167.81%
↓ 95.02%
FY21Y/Y Change
Revenue
9.3M
↓ 4.62%
Net Income
-11.4M
↓ 30.41%
Net Profit Margin
-122.43%
↑ 45.38%
FY22Y/Y Change
Revenue
10.5M
↑ 12.79%
Net Income
-11.3M
↓ 0.96%
Net Profit Margin
-107.51%
↑ 14.92%
FY23Y/Y Change
Revenue
9.4M
↓ 9.9%
Net Income
-18.0M
↑ 59.49%
Net Profit Margin
-190.31%
↓ 82.8%
Q4 FY22Q/Q Change
Revenue
2.7M
↑ 26.52%
Net Income
-3.4M
↑ 5.96%
Net Profit Margin
-128.29%
↑ 24.9%
Q1 FY23Q/Q Change
Revenue
2.6M
↓ 3.89%
Net Income
-5.1M
↑ 48.15%
Net Profit Margin
-197.74%
↓ 69.45%
Q2 FY23Q/Q Change
Revenue
2.3M
↓ 11.63%
Net Income
-2.3M
↓ 55.56%
Net Profit Margin
-99.43%
↑ 98.31%
Q3 FY23Q/Q Change
Revenue
2.2M
↓ 3.48%
Net Income
-3.6M
↑ 59.96%
Net Profit Margin
-164.77%
↓ 65.34%
Q4 FY23Q/Q Change
Revenue
2.4M
↑ 9.66%
Net Income
-7.0M
↑ 94.02%
Net Profit Margin
-291.52%
↓ 126.75%
Q1 FY24Q/Q Change
Revenue
2.4M
↑ 0.0%
Net Income
-7.0M
↑ 0.0%
Net Profit Margin
-291.52%
↑ 0.0%
FY18Y/Y Change
Total Assets
14.6M
↓ 68.87%
Total Liabilities
7.9M
↓ 51.04%
FY19Y/Y Change
Total Assets
15.2M
↑ 4.13%
Total Liabilities
14.3M
↑ 81.45%
FY20Y/Y Change
Total Assets
20.9M
↑ 37.11%
Total Liabilities
15.0M
↑ 4.84%
FY21Y/Y Change
Total Assets
20.7M
↓ 1.0%
Total Liabilities
17.3M
↑ 15.11%
FY22Y/Y Change
Total Assets
19.4M
↓ 6.13%
Total Liabilities
16.1M
↓ 6.91%
FY23Y/Y Change
Total Assets
11.2M
↓ 42.06%
Total Liabilities
14.8M
↓ 7.76%
Q4 FY22Q/Q Change
Total Assets
19.4M
↓ 3.52%
Total Liabilities
16.1M
↑ 1.49%
Q1 FY23Q/Q Change
Total Assets
19.8M
↑ 1.88%
Total Liabilities
14.7M
↓ 8.24%
Q2 FY23Q/Q Change
Total Assets
17.6M
↓ 10.85%
Total Liabilities
15.0M
↑ 1.64%
Q3 FY23Q/Q Change
Total Assets
15.9M
↓ 9.58%
Total Liabilities
12.7M
↓ 15.51%
Q4 FY23Q/Q Change
Total Assets
11.2M
↓ 29.45%
Total Liabilities
14.8M
↑ 17.05%
Q1 FY24Q/Q Change
Total Assets
11.2M
↑ 0.0%
Total Liabilities
14.8M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-7.0M
↓ 3.22%
Investing Cash Flow
-1.2M
↓ 11.25%
Financing Cash Flow
7.1M
↑ 32.32%
FY19Y/Y Change
Operating Cash Flow
-3.3M
↓ 53.32%
Investing Cash Flow
-182.0K
↓ 85.3%
Financing Cash Flow
4.2M
↓ 40.95%
FY20Y/Y Change
Operating Cash Flow
-14.4M
↑ 341.5%
Investing Cash Flow
-23.0K
↓ 87.36%
Financing Cash Flow
17.4M
↑ 314.91%
FY21Y/Y Change
Operating Cash Flow
-6.6M
↓ 54.01%
Investing Cash Flow
-93.0K
↑ 304.35%
Financing Cash Flow
6.8M
↓ 60.79%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.2M
↑ 18.2%
Investing Cash Flow
-771.0K
↑ 766.29%
Financing Cash Flow
1.5M
↑ 55.99%
Q1 FY23Q/Q Change
Operating Cash Flow
-615.0K
↓ 47.97%
Investing Cash Flow
-771.0K
↑ 0.0%
Financing Cash Flow
3.1M
↑ 97.61%
Q2 FY23Q/Q Change
Operating Cash Flow
-812.0K
↑ 32.03%
Investing Cash Flow
-590.0K
↓ 23.48%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Thermogenesis Holdings Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Thermogenesis Holdings Inc
Thermogenesis Holdings Inc
56.25%
-68.75%
-78.99%
-99.77%
-99.89%
Stryker Corporation
Stryker Corporation
10.37%
0.94%
19.75%
31.06%
67.96%
Boston Scientific Corp.
Boston Scientific Corp.
7.45%
23.41%
49.56%
83.54%
97.58%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
1.94%
-26.45%
-10.77%
-44.73%
-8.17%
Abbott Laboratories
Abbott Laboratories
5.62%
-5.27%
11.14%
-11.6%
36.83%
Medtronic Plc
Medtronic Plc
10.72%
5.13%
10.43%
-31.45%
-16.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Thermogenesis Holdings Inc
Thermogenesis Holdings Inc
NA
NA
NA
0.0
-8.02
-0.25
NA
0.12
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Thermogenesis Holdings Inc
Thermogenesis Holdings Inc
Buy
$3.2M
-99.89%
NA
-153.43%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
67.96%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
97.58%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-8.17%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
36.83%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.37%
30.16
12.06%

Insights on Thermogenesis Holdings Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.19M → 2.73M (in $), with an average increase of 10.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -7.01M → -1.85M (in $), with an average increase of 277.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.5% return, outperforming this stock by 129.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 83.5% return, outperforming this stock by 183.3%

Institutional Holdings

  • Raymond James & Associates

    0.82%

  • Vanguard Group Inc

    0.45%

  • Virtu Financial LLC

    0.33%

  • Geode Capital Management, LLC

    0.13%

  • Morgan Stanley - Brokerage Accounts

    0.12%

  • Tower Research Capital LLC

    0.09%

Company Information

thermogenesis holdings, inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (car)-t and other cell-based therapies. it markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed car-txpress platform, which streamlines the manufacturing process for the emerging car-t immunotherapy market. the company operates through two segments, device and clinical development. it manufactures and markets products for clinical bio-banking applications, including axp automated cell separation system, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and bioarchive automated cryopreservation system, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical appli

Organization
Thermogenesis Holdings Inc
Employees
25
CEO
Dr. Xiaochun Xu M.B.A., Ph.D.
Industry
Health Technology

Discover More

FAQs